|1.||Aloe, Luigi: 66 articles (01/2015 - 01/2002)|
|2.||Aloe, L: 43 articles (01/2015 - 01/2000)|
|3.||Lambiase, Alessandro: 28 articles (01/2015 - 10/2003)|
|4.||Cattaneo, Antonino: 28 articles (01/2015 - 09/2002)|
|5.||Micera, Alessandra: 23 articles (01/2015 - 06/2002)|
|6.||Bonini, Stefano: 23 articles (01/2015 - 10/2003)|
|7.||Kuo, Hann-Chorng: 23 articles (08/2014 - 09/2007)|
|8.||Lazarovici, Philip: 22 articles (07/2015 - 01/2002)|
|9.||Liu, Hsin-Tzu: 22 articles (08/2014 - 09/2007)|
|10.||Capsoni, Simona: 21 articles (01/2015 - 09/2002)|
03/31/2011 - "The observation that the majority of sensory nerve fibers innervating the skeleton express TrkA+, may in part explain why therapies that block NGF/TrkA pathway are highly efficacious in attenuating skeletal pain."
09/12/2008 - "NGF antagonism is expected to be a highly effective and safe therapeutic approach in many pain states. "
01/01/2014 - "The reduction of urinary NGF levels was significant in responders, with a reduction of pain and improved GRA."
01/01/2014 - "Urinary NGF and NGF/Cr levels significantly decreased in the responders with a VAS pain reduction by 2 (both p < 0.05) and the GRA improved by 2 (both p < 0.05), but not in non-responders. "
11/01/2009 - "Patients who responded to treatment and had an improvement in VAS pain score of > or =2 had significantly lower NGF/Cr levels than nonresponders who had a VAS improvement of <2. Patients with IC/BPS had greater urinary NGF/Cr levels than controls. "
|2.||Alzheimer Disease (Alzheimer's Disease)
04/01/1996 - "Since NGF-responsive basal forebrain cholinergic neurons are lost in Alzheimer's disease, treatment with NGF may be therapeutically beneficial for the patients with this disease. "
09/01/2005 - "But while NGF distinctly promoted neurite branching and elongation, Abeta was less effective in neurite elongation and counts of small processes and of growth cones remained clearly elevated after 24-h stimulation; these peculiarities might be linked to aberrant neuronal connections reported for an animal model of Alzheimer disease. "
04/13/1999 - "Effective NGF therapy required millimeter-scale positioning of the NGF source, and efficacy correlated with the spatial distribution of NGF concentration in the tissue; this result suggests that NGF must be delivered within several millimeters of the target to be effective in treating Alzheimer's disease. "
01/01/1990 - "NGF may possibly be useful for the treatment of memory and cognitive impairment as in senile dementia of Alzheimer's type."
08/01/2013 - "Recent studies have shown that the precursor of nerve growth factor (proNGF) is highly elevated in aging brains and in the brains of patients with Alzheimer's Disease. "
10/01/2011 - "The present study shows that NGF expressed in regenerating muscle cells is involved in persistent muscular mechanical hyperalgesia. "
01/16/2009 - "The present study addresses the question of whether EA can influence the hyperalgesia induced by NGF administration. "
01/01/2009 - "Many studies have focused on cutaneous mechanisms for NGF-induced hyperalgesia; few have examined its contribution in deeper tissues like muscle. "
01/01/2006 - "This study describes the development of a novel model of NGF-induced secondary hyperalgesia. "
11/01/1997 - "Although finding that NGF-induced hyperalgesia does not clearly correlate with changes in the release of SP-LI in the spinal cord, this study shows that NT-3 is an inhibitor of SP-LI release and suggests that this mechanism may be responsible for NT-3-induced antinociception."
|4.||Neuralgia (Stump Neuralgia)
01/01/2014 - "At 14 days post-injury, there was a significantly greater [NGF] ipsilaterally compared to contralaterally (ipsilateral = 111 ± 23 pg/mg, contralateral = 69 ± 13 pg/mg), but there was no behavioural evidence of neuropathic pain at this time-point. "
02/01/1999 - "However, anti-NGF but not NGF blocked collateral sprouting and decreased the severity of autotomy, suggesting that anti-NGF may be a better potential alternative analgesic for the treatment of neuropathic pain in humans. "
06/01/2003 - "We demonstrate that NGF cotreatment decreased the occurance of autotomy, suggesting a reduction of neuropathic pain, and improved the performance in motor and sensory tests. "
07/01/2014 - "We use ODE constrained mixture modelling to study NGF-induced Erk1/2 phosphorylation in primary sensory neurones, a process relevant in inflammatory and neuropathic pain. "
06/01/2011 - "Blocking the activity of nerve growth factor or enhancing the activity of either glial-derived neurotrophic factor or artemin has shown potential for normalizing neuronal activity and attenuating signs of neuropathic pain in animal models and clinical studies. "
|5.||Diabetic Neuropathies (Diabetic Neuropathy)
11/01/1994 - "These findings indicate that, while NGFR expression is normal in the STZ-diabetic neuropathy model, the marked decrease in receptor saturation observed in diabetics may reflect low peripheral NGF levels, which in consequence leads to the apparent deprivation of neuronal NGF in diabetic rats."
07/01/2002 - "These results suggest that gene transfer with an NGF-producing herpes-based vector may prove useful in the treatment of diabetic neuropathy."
11/01/1996 - "One study of NGF in patients with diabetic neuropathy found that the drug improved neurologic function and produced an increase in the patients' ability to sense cooling or painful heat. "
01/01/2011 - "However, the results of a phase 3 trial were moderate and, therefore, not enough to encourage widespread use of NGF in the treatment of diabetic neuropathy. "
02/01/2003 - "However, a phase 3 trial in diabetic neuropathy and a phase 2 trial in HIV-related neuropathy have failed to demonstrate any substantial effect of treatment with NGF. "
|1.||Nerve Growth Factor (NGF)
|2.||Brain-Derived Neurotrophic Factor (BDNF)
|4.||Nerve Growth Factors (Neurotrophins)
|5.||Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)
|7.||Ophthalmic Solutions (Eye Drops)
|8.||Messenger RNA (mRNA)
|9.||Glial Cell Line-Derived Neurotrophic Factor (GDNF)
|5.||Transplantation (Transplant Recipients)